This webinar aims to review and discuss data for liquid biopsy-based assessments as endpoints of antitumour activity in clinical trials, understand the potential and limitations of liquid biopsy-based tumour genomic profiling for patient stratification and detection of predictive biomarkers of response to therapy, and to discuss how tumour heterogeneity and evolution assessed via liquid biopsy assays may improve breast cancer treatment strategies.
The webinar will also offer the opportunity for real-time interaction between audience and experts.
Michail Ignatiadis, Pedram Razavi, Nicholas Turner
Welcome & Introduction, Dr. Monica Arnedos, Breast Cancer Unit, Institut Bergonié, Bordeaux, France
Integrating Liquid Biopsies in Clinical Trials and Clinical Practice for Breast Cancer, Dr. Michail Ignatiadis, Medical Oncology Department, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium
The Use of Liquid Biopsy Profiling for Prognosis, Biomarker Discovery and Patient Stratification in Breast Cancer, Dr. Pedram Razavi, Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, US
The Use of Liquid Biopsy Dynamics to Capture Tumour Evolution and Drug Resistance in Early and Advanced Breast Cancer, Prof. Nicholas Turner, Breast Unit, Royal Marsden; Institute of Cancer Unit, London, UK
Closing Remarks, Dr. Monica Arnedos, Breast Cancer Unit, Institut Bergonié, Bordeaux, France
- Understand how to integrate liquid biopsy in clinical trials for breast cancer patients in terms of concepts of patient identification to surrogates of standard endpoints
- Understand the use of liquid biopsy profiling in breast cancer for prognosis, biomarker discovery and patient stratification
- Understand the use of liquid biopsy dynamics to capture tumour evolution and drug resistance in breast cancer